argenx Announces Positive Phase 3 Results for Autoimmune Myositis Treatment

Key Facts

In a move reflecting the rapid advancement in the biotech sector to find solutions for rare diseases, argenx announced positive topline results from its ALKIVIA Phase 3 study. According to reports, the study met its primary endpoint, demonstrating a statistically significant 15.4-point greater improvement in mean Total Improvement Score (TIS) compared to the placebo group. The trial evaluated VYVGART Hytrulo in adults with autoimmune myositis, achieving a high statistical significance with a p-value of 0.0011.

These results are particularly significant as they mark the first Phase 3 study to show meaningful benefits for patients with the IMNM subtype, a condition that currently has no approved therapies. Per analyst data, the trial demonstrated clinically meaningful improvements in disease activity for both IMNM and DM subtypes. This development comes as specialized pharmaceutical firms strive to strengthen their portfolios of innovative immunological treatments to address unmet medical needs.

Regarding market performance, ARGX stock stood at $851.29 (at close August 14, 2026), after reaching a day high of $852.08. Looking ahead, investors are monitoring the U.S. Inflation Rate (CPI) data scheduled for August 12, 2026, which may impact risk appetite in the growth and biotech sectors, while attention remains focused on the company's next steps regarding regulatory approvals.